CLAIMS

1. Compound of the formula (I):

$$R_{2} \longrightarrow \begin{array}{c} R_{1} \\ O \\ N-C-(CH_{2})_{n}-N \end{array} \longrightarrow \begin{array}{c} CH_{2}-CH_{2} \\ N-R_{4} \end{array} \qquad (I)$$

5 in which:

- n is 1 or 2;
- R_1 represents a halogen atom; a trifluoromethyl radical; a (C_1-C_4) alkyl; a (C_1-C_4) alkoxy; a trifluoromethoxy radical;
- R₂ represents a hydrogen atom or a halogen atom;
 R₃ represents a hydrogen atom; a group -OR₅; a group
 -CH₂OR₅; a group -NR₆R₇; a group -NR₈COR₉; a group
 -NR₈CONR₁₀R₁₁; a group -CH₂NR₁₂R₁₃; a group -CH₂NR₈CONR₁₄R₁₅;
 a (C₁-C₄)alkoxycarbonyl; a group -CONR₁₆R₁₇;
- 15 or else R_3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;
 - R_4 represents the aromatic group 1,3-thiazol-2-yl of formula:

$$-$$

20

- R_5 represents a hydrogen atom; a (C_1-C_4) alkyl; a (C_1-C_4) alkylcarbonyl;
- R_6 and R_7 represent each independently a hydrogen atom or a (C_1-C_4) alkyl;

- R_8 represents a hydrogen atom or a (C_1-C_4) alkyl;
- R_9 represents a (C_1-C_4) alkyl or a group $(CH_2)_m$ - NR_6R_7 ;
- m is 1, 2 or 3;
- R_{10} and R_{11} represent each independently a hydrogen
- 5 atom or a (C_1-C_4) alkyl;
 - R_{12} and R_{13} represent each independently a hydrogen atom or a (C_1-C_5) alkyl;
 - R_{13} may also represent a group $-(CH_2)_q-OH$ or a group $-(CH_2)_q-S-CH_3$;
- 10 or else R_{12} and R_{13} , together with the nitrogen atom to which they are attached, constitute a heterocycle selected from aziridine, azetidine, pyrrolidine, piperidine and morpholine;
 - q is 2 or 3;
- 15 R_{14} and R_{15} represent each independently a hydrogen atom or a (C_1-C_4) alkyl;
 - R_{16} and R_{17} represent each independently a hydrogen atom or a (C_1-C_4) alkyl;

 R_{17} may also represent a group $-(CH_2)_q-NR_6R_7$;

- 20 or else R_{16} and R_{17} , together with the nitrogen atom to which they are attached, constitute a heterocycle selected from azetidine, pyrrolidine, piperidine, morpholine and piperazine which is unsubstituted or substituted in position 4 by a (C_1-C_4) alkyl;
- 25 in the form of a base or an addition salt with an acid, or in the form of a hydrate or solvate.
 - 2. Compound of formula (I) according to

Claim 1, characterized in that:

- n is 1:
- R_1 is in position 3 of the phenyl and represents a trifluoromethyl radical, a methyl, a methoxy or a trifluoromethoxy radical and R_2 represents a hydrogen atom; or else R_1 is in position 3 of the phenyl and represents a trifluoromethyl radical and R_2 is in position 4 of the phenyl and represents a chlorine atom:
- 10 R_3 represents a hydroxyl, a methoxy, an aminomethyl, a (methylamino)methyl, a (dimethylamino)methyl; or else R_3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;
- 15 R_4 represents a 1,3-thiazol-2-yl; in the form of a base or an addition salt with an acid, and also in the form of a hydrate or solvate.
- 3. Process for preparing compounds of
 formula (I) according to Claim 1 in which n = 1,
 20 characterized in that:
 - al) a compound of formula

$$R_{2}$$

$$N-C-CH_{2}-Hal$$
(IIa)

in which R_1 , R_2 and R_3 are as defined for a compound of formula (I) in Claim 1 and Hal represents a halogen 25 atom, preferably chlorine or bromine, with the proviso

that when R_3 contains a hydroxyl or amine function these functions may be protected, is reacted with a compound of formula

$$CH_2$$
 CH_2 $N-R_4$ (III)

5. in which R_4 is as defined for a compound of formula (I) in Claim 1;

bl) and, after deprotection of the hydroxyl or amine functions present in R_3 where appropriate, the compound of formula (I) is obtained.

4. Process for preparing compounds of formula (I) according to Claim 1 in which n=2, characterized in that:

a2) a compound of formula

$$R_2$$
 N -C-CH=CH₂ (IIb)

15

in which R_1 , R_2 and R_3 are as defined for a compound of formula (I) in Claim 1, with the proviso that when R_3 contains a hydroxyl or amine function these functions may be protected, is reacted with a compound of formula

$$CH_2$$
— CH_2
 $N-R_4$ (III)

20

in which R_4 is as defined for a compound of formula (I) in Claim 1;

- b2) and, after deprotection of the hydroxyl or amine functions present in R_3 where appropriate, the compound of formula (I) is obtained.
- 5. Process for preparing compounds of formula (I) according to Claim 1 in which R_3 represents a group $-CH_2NR_{12}R_{13}$ in which R_{12} and R_{13} each represent hydrogen, characterized in that:
 - a3) a compound of formula

10 in which R_1 and R_2 are as defined for a compound of formula (I) in Claim 1 and Hal represents a halogen atom, preferably chlorine or bromine, is reacted with a compound of formula

$$CH_2$$
— CH_2
 $N-R_4$ (III)
 CH_2 — CH_2

15 in which R_4 is as defined for a compound of formula (I) in Claim 1 to give a compound of formula

$$\begin{array}{c|c} R_{2} & O & CH_{2}-CH_{2} \\ \hline N-C-(CH_{2})_{n}-N & CH_{2}-CH_{2} \\ \hline N-R_{4} & (Ia) \end{array}$$

- b3) the cyano group of the compound of formula (Ia) is reduced to give a compound of formula (I) according to Claim 1 in which $R_3 = CH_2NH_2$.
 - 6. Compound of formula

in which:

- n is 1 or 2;
- R_1 represents a halogen atom; a trifluoromethyl radical; a (C_1-C_4) alkyl; a (C_1-C_4) alkoxy; a trifluoromethoxy radical;
 - R₂ represents a hydrogen atom or a halogen atom;
 - R_4 represents the aromatic group 1,3-thiazol-2-yl of formula:

, s

10

in the form of a base or an addition salt with an acid, or in the form of a hydrate or solvate.

- 7. Medicament, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 2, or an addition salt of this compound with a pharmaceutically acceptable acid, or else a hydrate or a solvate of the compound of formula (I).
 - 8. Pharmaceutical composition,
- 20 characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 2, or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, and at least one pharmaceutically acceptable excipient.

9. Use of a compound of formula (I)
according to any one of Claims 1 to 2 for the
preparation of a medicament intended for the prevention
or treatment of central or peripheral neurodegenerative
5 diseases; amyotrophic lateral sclerosis, multiple
sclerosis; cardiovascular conditions; peripheral
neuropathies; damage to the optic nerve and to the
retina; spinal cord trauma and cranial trauma;
atherosclerosis; stenoses; cicatrization; alopecia;
10 cancers; tumours; metastases; leukaemias; chronic
neuropathic and inflammatory pain; autoimmune diseases;
bone fractures; bone diseases.

C